In The Eye Of The Storm? Merck’s Quarter Is Bright, But Vioxx Cloud Looms
Executive Summary
Efforts to reinvigorate Merck's pipeline, cut costs and restore earnings growth paid off in the first quarter as the drug maker reignited investor enthusiasm
You may also be interested in...
Schering Expects Earnings Decline In Second Half, Despite Solid Start To 2006
Schering-Plough is bracing for a slowdown in the second half of 2006 as it increases its R&D spend and anticipates a drop off in sales for its seasonal products
Schering Expects Earnings Decline In Second Half, Despite Solid Start To 2006
Schering-Plough is bracing for a slowdown in the second half of 2006 as it increases its R&D spend and anticipates a drop off in sales for its seasonal products
New Scripts May Be Juiced By Plan Switches Accompanying Part D – IMS
The number of new prescriptions reported since the implementation of Medicare Part D could be artificially inflated due to patients changing plans